Your session is about to expire
← Back to Search
Lurbinectedin + Immunotherapy for Soft Tissue Sarcoma (LINNOVATE Trial)
LINNOVATE Trial Summary
This trial tests a potential cancer treatment using three drugs given intravenously in increasing doses.
LINNOVATE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.LINNOVATE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had vaccines for infectious diseases in the last 4 weeks.I am on immunosuppressive therapy or I am HIV positive.I have not had ongoing or uncontrolled diarrhea in the last 4 weeks.I haven't had cancer treatment like radiation or chemotherapy in the last 3 weeks.I am unable or unwilling to follow the study rules.I have an autoimmune disease like rheumatoid arthritis or lupus.I have heart failure or had a recent heart problem.I have a condition affecting my adrenal glands.My brain metastases are treated, and I've been stable without steroids for 2 weeks.I haven't had recent severe gut issues like diverticulitis or blockages.I am 18 years old or older.My sarcoma cannot be surgically removed and has spread.I am fully active and can carry on all my pre-disease activities without restriction.I have a hormone disorder caused by my pituitary gland.I have cancer cells in the fluid around my brain and spinal cord.I have received immunotherapy targeting CTLA4 or PD-1.I have (not) been treated before and am interested in Phase 1 (Phase 2) of the study.My blood counts are within normal ranges without needing help from medications or transfusions recently.My skin condition affects more than a quarter of my body.I have inflammatory bowel disease (Crohn's or ulcerative colitis).I understand the study's risks and have signed the consent form.I am not pregnant or breastfeeding.My kidney function is within the normal range.My liver functions within normal limits, or close to it, even if I have liver metastases.
- Group 1: Phase 1/2 study using lurbinectedin, ipilimumab and nivolumab for advanced soft tissue sarcoma
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the research project currently accepting volunteers over a certain age?
"Participants must be of legal age (18+) and not exceed 90 years old to qualify for this medical trial."
Can I register for involvement in this medical experiment?
"This clinical trial is recruiting approximately 40 participants who have a diagnosis of soft tissue sarcoma and between the ages of 18 to 90 years old."
Is there an ongoing recruitment process for this clinical experiment?
"As per the clinicaltrials.gov listing, this research is still open to enrolment. The study was inaugurated on June 7th 2021 and has been recently updated on that same date."
How many individuals are being enrolled in this research project?
"Affirmative. Information accessible on clinicaltrials.gov reveals that this investigation is accepting new participants, which was initially posted on June 7th 2023 and last revised the same day. There are 40 vacancies at a single medical centre for potential enrollees."
Share this study with friends
Copy Link
Messenger